Three-dimensional dynamic contrast-enhanced MRI has potential for the assessment of disease severity as indicated by PVR and MPAP in patients with primary pulmonary hypertension.
Observational
Does 3D dynamic contrast-enhanced MR perfusion accurately assess disease severity (PVR and MPAP) in patients with primary pulmonary hypertension?
3D dynamic contrast-enhanced MRI may be a useful non-invasive tool to assess disease severity (PVR and MPAP) in patients with primary pulmonary hypertension.
OBJECTIVE: The purpose of this study was to determine whether quantitative pulmonary perfusion parameters obtained from 3D dynamic contrast-enhanced MR perfusion data can be used to assess the severity of primary pulmonary hypertension (PPH) as indicated by pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (MPAP). CONCLUSION: Three-dimensional dynamic contrast-enhanced MRI has potential for assessment of disease severity as indicated by PVR and MPAP in patients with PPH.
Ohno et al. (2006) conducted an observational in Primary pulmonary hypertension (PPH). 3D dynamic contrast-enhanced MR perfusion was evaluated on Disease severity as indicated by pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (MPAP). Three-dimensional dynamic contrast-enhanced MRI has potential for the assessment of disease severity as indicated by PVR and MPAP in patients with primary pulmonary hypertension.